activins has been researched along with thalidomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Papatheodorou, A; Terpos, E | 1 |
| Cirstea, D; Eda, H; Fulciniti, M; Mahindra, A; Nemani, N; Patel, K; Raje, N; Santo, L; Scullen, T; Vallet, S; Yee, A | 1 |
2 other study(ies) available for activins and thalidomide
| Article | Year |
|---|---|
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Topics: Activins; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2012 |
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
Topics: Activins; Angiogenesis Inhibitors; Antibodies, Neutralizing; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Humans; Lenalidomide; MAP Kinase Signaling System; Multiple Myeloma; Osteoblasts; Stromal Cells; Thalidomide | 2013 |